Intas Biopharmaceuticals win GOLD award for Quality Excellence

Ahmedabad, January 27, 2010: Intas Biopharmaceuticals Limited, India’s premier biopharmaceutical organization, has received GOLD Award for Quality Excellence in the category of Formulations Unit. The award was conferred by Indian Drug Manufacturer’s Association (IDMA) on January 16, 2010 during its Annual Day Celebrations. The awards were presented by B. S. Jharwar, Chairman, National Pharmaceutical Pricing Authority (NPPA) and Devender Choudhary, Joint Secretary, Department of Pharmaceuticals. From company’s end, Mr. Hitesh Patel, Sr. Manager (Quality Assurance) and Mr. Ravindra Wagh, Head (Formulation Manufacturing) were present to receive the award.

Intas Biopharmaceuticals Limited has received a GOLD trophy from IDMA for the second time in a row as it received this prestigious award of Quality Excellence consecutively in 2008 and 2009.

Speaking on the development, Dr. Rustom Mody, Chief Scientific Officer and Director (Quality), Intas Biopharmaceuticals Limited, said, “The GOLD award reiterates Intas’ commitment towards maintaining superior Quality Standards and consistently improve the standards based on international norms and regulations. The GOLD award is a recognition from IDMA of our untiring efforts towards quality enhancement as we look ahead to adhere to regulations framed by USFDA.

Intas Biopharmaceuticals, is in the process of scaling up its Quality portfolio by undergoing quality audits that has not just strengthened processes / systems but also aligning them as per USFDA regulations. International regulatory bodies including MCC-South Africa, GCC, Syria, Yemen and European Union has granted us GMP certifications which validates and authenticates our quality commitment.”

In the Biopharmaceutical segment, Intas has became a leading company to register a Year-on-Year (YoY) growth of more than 85 percent thereby increasing its market share to 50 percent in 2009 from previous year’s 40 percent. Company has made a strategic foray of developing products for regulated markets, which is the major driver in terms of growth contribution. Today, Intas can boost of having its biosimilar drugs successfully under clinical trials in EU, have marketing arrangements for its products in EU as well as the North American market, which is the biggest in the world. In addition, the company within India has entered into alliances and marketing arrangement with other companies, which is increasing its market presence and penetration.

Intas Biopharmaceuticals Limited is first & only EU-GMP, MCC & GCC approved biotech facility, which reflects an in-depth understanding of global regulatory aspects in biosimilars. Global business operation is based on ‘out-licensing model’, which enable company to run its low investment, lower risk & considerable margin based operation.

At the international front, Intas Biopharmaceuticals Limited is the first Indian Biotech Company to plan biosimilars for the European markets. Apart from regulated markets of North America & Europe, where the company has aggressive plans to launch its biotech products, it also has considerable presence in semi-regulated markets of South East Asia, Latin America, Middle East, Russia & CIS countries and Africa.

With its integrated product portfolio and services offered, company is uniquely positioned to serve as a strategic global partner to the industry’s leading players with a very competitive pricing structure. Despite stiff competition, company’s success factor can be noticed from the fact that in the shortest span of time, its range of biosimilar products have been developed, launched and marketed successfully with the help of dedicated product and business development teams.

The company has practiced licensing for all its bio-similar products, currently it has out-licensed its four products in all major territories across the globe. Company’s business operation is based on effective & professional partnership with its business associates, which have resulted quicker regulatory approvals & profitable exports for Rest of the World (ROW) markets. Our European Clinical has shown very positive result, which has given sense of confidence to our group of business associates.

Since launch of biotechnology operations in May 2000, research & development, manufacturing and marketing of biopharmaceutical products, with a special focus on Oncology (Cancer), are major thrust areas for IBPL. The company is India’s first and only biopharmaceuticals manufacturing company to receive European Union – Good Manufacturing Practice (EU-GMP) certification and South African Medicines Control Council certification for GMP. Today, Intas Biopharmaceuticals Limited is the sole manufacturer to commercialize pegylated GCSF and markets under the brand name “NEUPEG™”. IBPL has launched four biosimilar products Neukine™ (rHu G-CSF), Erykine™ / Epofit™ (rHu EPO), Intalfa™ (rHu IFN Alfa-2b) and Neupeg™ (rHu Peg GCSF) and marketing in India and international markets. The company is working on seven more biosimilar products, which will be launched in next 3 years in various markets.

Siddharth J. Baad, Corporate Communications
Intas Biopharmaceuticals Limited
Safal Pegasus, 904-909, A Block,
Nr. Prahladnagar Garden, Anandnagar,
Satellite, Ahmedabad – 380015
Phone: 0091-79-66112501 / 02
Fax: 0091-79-66112500

This release was published on openPR.